Alemtuzumab, cladribine, fingolimod, and natalizumab as first-line treatments in adult patients with highly active relapsing multiple sclerosis

CADTH
Record ID 32018012109
English
Details
Project Status: Ongoing
Anticipated Publish Date: 2024
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Multiple Sclerosis
  • Multiple Sclerosis, Relapsing-Remitting
  • Alemtuzumab
  • Cladribine
  • Fingolimod Hydrochloride
  • Natalizumab
  • Rituximab
  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
Contact
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: <p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.